Harry Aaldenberg

MUbio Products B.V. (MUbio) is a privately owned Dutch biotech company, founded in 2000 by Dr. R. Vleugels and Prof. Dr. F. Ramaekers. The company originated as a spin out from the Department of Molecular Cell Biology of the Maastricht University. MUbio produces high quality reagents and bioassays for cell biology and biomedical research. MUbio's product portfolio includes an increasing number of well-characterized antibodies for oncology research, produced in an ISO certified laboratory. MUbio’s partnered and proprietary R&D projects focus on the identification and validation of cancer biomarkers, development of lung cancer diagnostic kits & research and development of a lung cancer vaccine.

IQ Corporation is a life sciences company based in The Netherlands. Its mission is to contribute to human healthcare through the development and worldwide commercialization of products for diagnostic and therapeutic applications. The company's therapeutics division (IQ Therapeutics) is applying its Cloning the Human Response(TM) technology for its own pipeline and third parties' to generate and develop fully human antibodies from immunized or vaccinated donors for the prevention and treatment of infectious diseases. The company's diagnostic products division (IQ Products www.iqproducts.nl) has developed a range of products for flow-cytometry and for perinatal, transplantation and sepsis related diagnosis, which are sold in more than 50 countries. NOM NV and Zernike Seed Fund BV are the major shareholders in IQ Corporation.